BioPharma Dealmakers

@bpdealmakers

Dedicated to nurturing collaboration and partnerships in the biopharma industry, from the publishers of Nature.

Vrijeme pridruživanja: ožujak 2016.

Tweetovi

Blokirali ste korisnika/cu @bpdealmakers

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @bpdealmakers

  1. Prikvačeni tweet
    4. pro 2019.

    Introducing our first December issue....as usual we include a variety of and companies looking to partner. Our editorials cover deals targeting the complement cascade and a review of the year's high value partnering deals.

    Poništi
  2. 17. sij

    We're preparing our content for our first issue of 2020. In the meantime, check out who have developed an affordable off-the-shelf cell therapy product indicated for

    Poništi
  3. proslijedio/la je Tweet

    2019 FDA drug approvals The FDA approved 48 new drugs last year, keeping up the momentum of recent years - find out more about them in our annual analysis by

    Poništi
  4. 3. sij

    2019 saw a boom in high-value M&A and licensing deals, with oncology and rare diseases as prominent themes. Look back on such deals in our round up article from our December Issue

    Poništi
  5. "Biopharmas targeting common viral denominators to battle flu"

    Poništi
  6. Happy 25th Birthday to ! Another productive and well organised conference. Don't forget to pick your copy up of our edition for the journey home or read online.

    Poništi
  7. proslijedio/la je Tweet
    6. stu 2019.

    This week on the Nature cover: 150 years of Nature. A web of multidisciplinary research and discovery. Browse the issue here:

    Poništi
  8. 5. stu 2019.

    The November issue is now available, featuring companies targeting including Our editorials also focus on the virus and the art of closing a deal Read the full issue here

    Poništi
  9. proslijedio/la je Tweet
    4. stu 2019.

    Read the first article published in Nature written by T. H. Huxley that was issued on this date in 1869.

    Poništi
  10. The search for checkpoint inhibitor partners: Immuno-oncology continues to be a highly active area for dealmaking as leading companies seek to expand the treatable patient population for checkpoint inhibitors

    Poništi
  11. "Wafermine: the world’s first patented sublingual racemic ketamine wafer for pain and depression." is transferring approved drugs into novel therapies to develop therapies for pain, depression and other conditions

    Poništi
  12. Biopharma dealmaking: negotiating your term sheet. Lubor Gaal, senior VP, Head of Europe of discusses how licensors can negotiate the best terms for their biopharma assets in our September issue

    Poništi
  13. Which companies were involved with the biggest deals of summer 2019? One deal involved and another Read about the deals that made headlines in July and August in our deals collection.

    Poništi
  14. 9. lis 2019.

    Developers of AlivaMab Mouse and AlivaMab Discovery Services, offer customized and streamlined solutions for companies and organisations looking to obtain efficacious and derisked therapeutic

    Poništi
  15. 8. lis 2019.

    "Delivering digital cell biology at light speed" Read about , pioneer and leader in the emerging field of digital cell biology, delivering breakthrough technology and platforms that fundamentally change research

    Poništi
  16. 3. lis 2019.

    Read how is advancing its lead antibody candidate through the clinic, whilst also developing a portfolio of clinical candidates that target key molecules implicated in , angiogenesis and immune surveillance in our September issue

    Poništi
  17. 1. lis 2019.

    Read how are tackling key challenges in the life sciences with advanced biological tools in our September issue, online now.

    Poništi
  18. proslijedio/la je Tweet
    3. ruj 2019.

    We’re featured in the SEP issue of ! As said, “We are integrating advanced technologies, including AI platforms, to fuel a new wave of innovative therapies that address resistance pathways that can significantly improve treatment of patients with cancer.”

    Poništi
  19. "Immaculate therapeutic antibody discovery" Harnessing its antibody discovery platform Symplex, has developed a fully integrated approach to discovering and developing next-generation antibody therapeutics.

    Poništi
  20. proslijedio/la je Tweet
    19. ruj 2019.

    "Our research communities allow scientists to tell the stories behind their research. Today over 2,500 authors have written a Behind the Paper post." James Butcher on how drive engagement and connection with their online communities.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·